Diagnostic Partnering Agreements Discussed in New In-demand Report Published at MarketPublishers.com27 Jan 2012 • by Natalie Aster
LONDON – The better half of deals entered into by the leading healthcare companies are discovery or development stage whereby the licensee accrues a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Realizing the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what can be achieved during the negotiation of terms. With a host of smaller companies seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered.
New research report “Diagnostics Partnering Terms and Agreements” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.
Diagnostics Partnering Terms and Agreements
Published: February 2012
Price: US$ 2.695,00
The report is aimed at providing an in-depth understanding of the diagnostic trends and structure of deals entered into by the top healthcare companies from pole to pole, as well as explaining how and why these companies enter these deals.
- trends in diagnostic dealmaking in the biopharma industry since 2007;
- analysis of diagnostic deal structure;
- case studies of real-life diagnostic deals;
- access to over 2,900 diagnostic contract documents;
- the leading diagnostic deals by value since 2007;
- most active diagnostic dealmakers since 2007;
- the leading diagnostic partnering resources.
The available contracts are listed by headline value; stage of development at signing; deal component type; specific therapy target.
More new research reports by the publisher can be found at CurrentPartnering page.